Maze Therapeutics (MAZE) Balance Sheet: Assets & Liabilities

Maze Therapeutics (MAZE) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Maze Therapeutics reported total assets of $397.13M and total liabilities of $42.16M. Shareholders' equity was $354.97M, up 80.3% from $196.90M a year earlier. Total debt stood at $23.31M against $341.92M in cash and short-term investments, a net cash position of $318.61M. That puts debt-to-equity at 0.07, compared with 0.14 a year earlier.

Maze Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Maze Therapeutics, Inc. (MAZE) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2022
Period ending	Dec 2025	Mar 2025	Dec 2024	Dec 2023	Dec 2022
Current Assets
Cash and Cash Equivalents	189.25	196.81	196.81	29.16	99.92
Short-Term Investments	152.67	0.00	-	0.00	0.00
Cash & Short-Term Investments	341.92	196.81	196.81	29.16	99.92
Accounts Receivable	0.00	0.00	-	0.00	0.00
Inventory	0.00	0.00	-	0.00	0.00
Other Current Assets	7.80	4.86	4.86	4.95	6.23
Total Current Assets	349.72	201.67	201.67	34.11	106.15
Non-Current Assets
Property, Plant & Equipment (Net)	25.16	29.92	29.92	34.98	41.23
Long-Term Investments	18.11	1.09	-	1.09	1.21
Other Non-Current Assets	4.14	7.87	8.95	2.41	2.58
Total Non-Current Assets	47.41	38.87	38.87	37.39	43.81
Total Assets	397.13	240.54	240.54	71.50	149.96
Current Liabilities
Accounts Payable	1.79	1.94	1.94	2.02	1.59
Short-Term Debt	4.80	4.63	-	4.49	4.32
Accrued Liabilities	5.11	-	14.10	2.93	14.87
Other Current Liabilities	15.97	14.10	-	9.81	14.87
Total Current Liabilities	22.56	20.67	20.67	16.32	20.78
Non-Current Liabilities
Long-Term Debt	18.51	22.00	22.00	20.08	27.73
Other Non-Current Liabilities	1.09	0.97	0.97	0.00	0.00
Total Non-Current Liabilities	19.61	22.97	22.97	429.04	27.73
Total Liabilities	42.16	43.64	43.64	445.35	48.51
Stockholders' Equity
Common Stock	0.05	0.00	0.00	0.00	0.00
Retained Earnings	-489.55	-358.43	-358.43	-395.69	-295.27
Accumulated Other Comprehensive Income	0.11	0.00	-	0.00	0.00
Additional Paid-in Capital	844.35	47.24	47.24	21.84	12.81
Shares Outstanding	49.34	-	43.78	43.78	43.78
Total Stockholders' Equity	354.97	196.90	196.90	-373.85	101.44
Total Liabilities & Equity	397.13	240.54	240.54	71.50	149.96

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Maze Therapeutics Balance Sheet

How much debt does Maze Therapeutics have?

Maze Therapeutics had total debt of $23.31M as of Dec 31, 2025, against $341.92M in cash and short-term investments. Its debt-to-equity ratio was 0.07. Total debt was $26.63M a year earlier.

What are Maze Therapeutics's total assets?

Maze Therapeutics reported total assets of $397.13M as of Dec 31, 2025, up 65.1% from $240.54M a year earlier. Total liabilities were $42.16M.

What is Maze Therapeutics's shareholders' equity?

Maze Therapeutics's shareholders' equity was $354.97M as of Dec 31, 2025, or about $7.19 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition